原发性嗜酸粒细胞增多症的诊断与治疗

王健民; 龚胜蓝

doi:10.13201/j.issn.1004-2806.2021.11.001

原发性嗜酸粒细胞增多症的诊断与治疗

王健民^,,
龚胜蓝

- 海军军医大学第一附属医院(上海长海医院)血液科(上海, 200433)
基金项目:
国家自然科学基金（No：81530047、81870143）

详细信息

通讯作者: 王健民,E-mail:jmwangch@139.com

中图分类号: R557.5

收稿日期: 2021-08-31

Diagnosis and treatment of primary hypereosinophilia

WANG Jianmin^,,
GONG Shenglan

More Information

Corresponding author: WANG Jianmin, E-mail: jmwangch@139.com

Received Date: 31 August 2021

摘要

- 原发性嗜酸粒细胞增多症 /
- 诊断 /
- 治疗
- hypereosinophilia /
- diagnosis /
- treatment

HTML全文

参考文献(41)

[1]	Crane MM, Chang CM, Kobayashi MG, et al.Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidencef[J].J Allergy Clin Immunol, 2010, 126(1):179-181.
[2]	Valent P, Klion AD, Horny HP, et al.Contemporary consensus proposalon criteria and classification of eosinophilic disorders and related syndromes[J].J Allergy Clin Immunol, 2012, 130(3):607-612.
[3]	中华医学会血液学分会白血病淋巴瘤学组.嗜酸粒细胞增多症诊断与治疗中国专家共识(2017年版)[J].中华血液学杂志, 2017, 38(7):561-565.
[4]	Bain BJ, Horny HP, Arber DA, et al.Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2[M]//Swerdlow SH, Campo E, Harris NL, et al.WHO classification of Tumours of Haematopoietic and Lymphoid Tissues.Revised 4th edition.Lyon, 2017:71-80.
[5]	Bain BJ, Horny HP, Hasserjian RP, et al.Chronic eosinophilic leukaemia, NOS[M]//Swerdlow SH, Campo E, Harris NL, et al.WHO classification of Tumours of Haematopoietic and Lymphoid Tissues.Revised 4th edition.Lyon, 2017:54-56.
[6]	Shomali W, Gotlib J.World Health Organization-defined eosinophilic disorders:2019 update on diagnosis, risk stratification, and management[J].Am J Hematol, 2019, 94:1149-1166.
[7]	RohmerJ, Couteau-Chardon A, Trichereau J, et al.Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia:Data from 151 patients[J].Am J Hematol, 2020, 95(11):1314-1323.
[8]	Ogbogu PU, Bochner BS, Butterfield JH, et al.Hypereosinophilic syndromes:a multicenter, retrospective analysis of clinical characteristics and response to therapy[J].J Allergy Clin Immunol, 2009, 124(6):1319-1325.
[9]	王柔嘉, 胡晓霞, 郭孟乔, 等.伴有嗜酸粒细胞增多和PDGFRA/B异常的髓系肿瘤三例并文献复习[J].白血病·淋巴瘤, 2018, 27(12):744-749.
[10]	Nagata A, Doki N, Harada H, et al.Late appearance of eosinophilia in myeloid blast phase of myeloid neoplasm with rearrangement of PDGFRβ[J].Leuk Lymphoma, 2020, 61(7):1736-1739.
[11]	Reiter A, Gotlib J.Myeloid neoplasms with eosinophilia[J].Blood, 2017, 129(6):704-714.
[12]	Goasguen JE, Bennett JM, Bain BJ, et al.The role of eosinophil morphology in distinguishing between reactive eosinophilia and eosinophilia as a feature of a myeloid neoplasm[J].Br J Haematol, 2020, 191(3):497-504.
[13]	龚胜蓝, 邱慧颖, 王健民.原发性嗜酸性粒细胞增多症的诊断分型与治疗进展[J].中华内科杂志, 2010, 49(10):894-896.
[14]	Naymagon L, Marcellino B, Mascarenhas J.Eosinophilia in acute myeloid leukemia:Overlooked and underexamined[J].Blood Rev, 2019, 36:23-31.
[15]	Jan M, Grinshpun DE, Villalba JA, et al.A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia[J].Blood Adv, 2020, 4(3):445-448.
[16]	Such E, Liquori A, Mora E, et al.RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib[J].Acta Haematol, 2019, 142(2):92-97.
[17]	Snider JS, Znoyko I, Lindsey KG, et al.Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses:Characterization of a cryptic t(9;22) (p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia[J].Cancer Genet, 2020(246-247):44-47.
[18]	Cools J, DeAngelo DJ, Gotlib J, et al.A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome[J].N Engl J Med, 2003, 348(13):1201-1214.
[19]	Golub TR, Barker GF, Lovett M, et al.Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation[J].Cell, 1994, 77(2):307-316.
[20]	Bourrienne MC, Debus J.Abnormal mast cells in myeloid neoplasm with eosinophilia and PDGFRB rearrangement[J].Blood, 2019, 134(8):718.
[21]	张春玲, 唐古生, 郭孟乔, 等.FGFR1基因异常在血液肿瘤中的临床意义[J].中国实验血液学杂志, 2020, 28(3):983-988.
[22]	Mattis DM, Wang SA, Lu CM.Contemporary Classification and Diagnostic Evaluation of Hypereosinophilia[J].Am J Clin Pathol, 2020, 154(3):305-318.
[23]	Jackson CC, Medeiros LJ, Miranda RN.8p11 myeloproliferative syndrome:a review[J].Hum Pathol, 2010, 41(4):461-476.
[24]	Stewart K, Carstairs KC, Dubé ID, et al.Neutrophilic myelofibrosis presenting as Philadelphia chromosome negative BCR non-rearranged chronic myeloid leukemia[J].Am J Hematol, 1990, 34(1):59-63.
[25]	Tang G, Sydney Sir Philip JK, Weinberg O, et al.Hematopoietic neoplasms with 9p24/JAK2 rearrangement:a multicenter study[J].Mod Pathol, 2019, 32(4):490-498.
[26]	Bain BJ, Ahmad S.Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?[J].Br J Haematol, 2014, 166(6):809-817.
[27]	Roberts KG, Li Y, Payne-Turner D, et al.Targetable Kinase activating lesions in Ph-like acute lymphoblastic leukemia[J].N Engl J Med, 2014, 371(11):1005-1015.
[28]	Falchi L, Mehrotra M, Newberry KJ, et al.ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant[J].Leukemia, 2014, 28(10):2090-2092.
[29]	Spitzer B, Dela Cruz FS, Ibanez Sanchez GD, et al.ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant:an entity distinct from JMML[J].Blood Adv, 2021, 5(7):1899-1902.
[30]	Xie W, Wang SA, Hu S, et al.Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors[J].Cancer Genet, 2018, 41(228-229):41-46.
[31]	Wang SA, Tam W, Tsai AG, et al.Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified[J].Mod Pathol, 2016, 29(8):854-864.
[32]	Cross NCP, Hoade Y, Tapper WJ, et al.Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia[J].Leukemia, 2019, 33(2):415-425.
[33]	Schwaab J, Umbach R, Metzgeroth G, et al.KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance[J].Am J Hematol, 2015, 90(9):774-777.
[34]	Helbig G, Soja A, Bartkowska-Chrobok A, et al.Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation[J].Am J Hematol, 2012, 87(6):643-645.
[35]	Lierman E, Michaux L, Beullens E, et al.FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib[J].Leukemia, 2009, 23(5):845-851.
[36]	Cheah CY, Burbury K, Apperley JF, et al.Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable longterm remissions with imatinib[J].Blood, 2014, 123(23):3574-3577.
[37]	刘云涛, 赵佳炜, 冯娟, 等.伴嗜酸性粒细胞增多和FGFR1重排髓系/淋系肿瘤五例报告及文献复习[J].中华血液学杂志, 2019, 40(10):848-852.
[38]	Kasbekar M, Nardi V, Dal Cin P, et al.Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia[J].Blood Adv, 2020, 4(13):3136-3140.
[39]	Verstovsek S, Subbiah V, Masarova L, et al.Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor[J].Ann Oncol, 2018, 29(8):1880-1882.
[40]	Schwaab J, Naumann N, Luebke J, et al.Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes[J].Am J Hemato, 2020, 95(7):824-833.
[41]	Yao J, Xu L, Aypar U, et al.Myeloid/lymphoid neoplasms with eosinophilia/basophilia and ETV6-ABL1 fusion:cell-of-origin and response to tyrosine kinase inhibition[J].Haematologica, 2021, 106(2):614-618.